Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
495.4 USD | +2.85% | -2.52% | -5.91% |
May. 30 | JPMorgan Adjusts Price Target on UnitedHealth to $559 From $546 | MT |
May. 30 | Baird Initiates UnitedHealth Group With Outperform Rating, $597 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With a 2024 P/E ratio at 27.3 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.91% | 456B | B- | ||
+14.19% | 125B | A- | ||
+15.08% | 97.9B | B- | ||
-21.78% | 43.15B | A- | ||
-3.53% | 38.2B | B- | ||
-12.93% | 18.43B | B- | ||
-27.51% | 2.57B | C+ | ||
-8.59% | 1.51B | B- | ||
+15.53% | 546M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UNH Stock
- Ratings UnitedHealth Group Inc.